Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series.
COVID-19
Case series
Compassionate use
Ribavirin aerosol
SARS-CoV-2
Virazole
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
04
2021
accepted:
28
06
2021
pubmed:
25
7
2021
medline:
25
7
2021
entrez:
24
7
2021
Statut:
ppublish
Résumé
Ribavirin is an inosine monophosphate dehydrogenase inhibitor with demonstrated activity against coronaviruses, including SARS-CoV-2. Five hospitalized patients with COVID-19 (confirmed by positive tests for SARS-CoV-2) received treatment with ribavirin for inhalation solution (ribavirin aerosol) as part of a compassionate use program. Patients included four men and one woman, with an age range of 29-72 years. Patients were managed according to international and Italian treatment guidelines for COVID-19. In addition, therapy with ribavirin aerosol 100 mg/mL was administered for 30 min twice daily for 6 days (i.e., 12 doses) in all patients. In order to address concerns about a possible increase in viral dispersal with the use of a nebulizer, healthcare providers remained outside the patient room during ribavirin aerosol administration. Pretreatment chest computed tomography (CT) scans showed pseudonodular areas of parenchymal thickening in the upper right lobe with associated ground glass opacities, multiple areas of parenchymal consolidation in both lower lobes with associated ground glass opacities, bilateral parenchymal thickening and multiple associated ground glass areas, or focal ground glass areas in the upper lobes bilaterally, which were almost completely resolved (three patients) or moderately cleared (one patient) on imaging at the end of ribavirin treatment. For a fifth patient, CT scans showed a stable pulmonary picture at the end of ribavirin treatment. No adverse reactions to ribavirin treatment were observed in any of the five patients. All patients recovered fully, and nasopharyngeal swabs obtained after hospital discharge tested negative for SARS-CoV-2. Ribavirin aerosol appears to be efficacious in the treatment of patients with COVID-19. A controlled trial of ribavirin aerosol is ongoing and will provide additional data across a broader patient population.
Identifiants
pubmed: 34302258
doi: 10.1007/s40121-021-00493-9
pii: 10.1007/s40121-021-00493-9
pmc: PMC8302211
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2791-2804Subventions
Organisme : Bausch Health, Bridgewater, NJ
ID : Provision of study medication and equipment for drug administration; funding for technical editorial and medical writing assistance
Informations de copyright
© 2021. The Author(s).
Références
Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26:729–34.
doi: 10.1016/j.cmi.2020.03.026
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35–6.
doi: 10.1016/S0140-6736(20)30305-6
Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74.
doi: 10.1038/s41577-020-0311-8
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
doi: 10.1016/S0140-6736(20)30183-5
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.
doi: 10.1016/S2213-2600(20)30076-X
Artese A, Svicher V, Costa G, et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist Updat. 2020;53:10072.
doi: 10.1016/j.drup.2020.100721
Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109:2903–28.
doi: 10.1021/cr900021w
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248: 117477.
doi: 10.1016/j.lfs.2020.117477
Copegus (ribavirin, USP) Tablets [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2005
Ribavirin 200 mg film-coated tablets [package insert]. South Ruislip, UK: Aurobindo Pharma—Milpharm Ltd.; 2020.
Virazole (ribavirin for inhalation solution, USP) prescribing information [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2019.
Virazole (ribavirin for inhalation) Solution, USP [product monograph]. Leval, Quebec, Canada: Bausch Health Canada Inc; 2020.
Knight V, Wilson SZ, Quarles JM, et al. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981;318:945–9.
doi: 10.1016/S0140-6736(81)91152-1
Wilson SZ, Gilbert BE, Quarles JM, et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984;26:200–3.
doi: 10.1128/AAC.26.2.200
Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985;27:309–13.
doi: 10.1128/AAC.27.3.309
Gilbert BE, Wyde PR, Ambrose MW, Wilson SZ, Knight V. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 1992;17:33–42.
doi: 10.1016/0166-3542(92)90088-M
Wyde PR, Wilson SZ, Petrella R, Gilbert BE. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 1987;7:211–20.
doi: 10.1016/0166-3542(87)90029-5
Gilbert BE, McLeay MT. MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res. 2008;78:223–9.
doi: 10.1016/j.antiviral.2008.01.005
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–6.
doi: 10.1136/thorax.2003.012658
Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3:1686.
doi: 10.1038/srep01686
Zhou C, Gao C, Xie Y, Xu M. COVID-19 with spontaneous pneumomediastinum. Lancet Infect Dis. 2020;20:510.
doi: 10.1016/S1473-3099(20)30156-0
Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–704.
doi: 10.1016/S0140-6736(20)31042-4
Nyström K, Waldenström J, Tang KW, Lagging M. Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Future Virol. 2019;14:153–60.
doi: 10.2217/fvl-2018-0166
Smith DW, Frankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24–9.
doi: 10.1056/NEJM199107043250105
Minnesota Department of Health. Aerosol-generating procedures and patients with suspected or confirmed COVID-19. St. Paul: Minnesota Department of Health; 2020.